Stockscreener 앱 받기
16.98
2.41%
0.40
시장 영업 전:
16.77
-0.21
-1.24%
전일 마감가:
$16.58
열려 있는:
$16.74
하루 거래량:
2.69M
Relative Volume:
1.04
시가총액:
$13.17B
수익:
$220.00K
순이익/손실:
$-1.08B
주가수익비율:
-11.75
EPS:
-1.4448
순현금흐름:
$-326.53M
1주 성능:
+8.85%
1개월 성능:
+2.35%
6개월 성능:
-19.75%
1년 성능:
-16.44%
1일 변동 폭
$16.74
$17.54
1주일 범위
$15.36
$18.24
52주 변동 폭
$13.83
$36.91
Summit Therapeutics Inc Stock (SMMT) Company Profile
명칭
Summit Therapeutics Inc
전화
305-203-2034
주소
601 BRICKELL KEY DRIVE, MIAMI
Compare SMMT vs VRTX, REGN, ARGX, ALNY, INSM
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SMMT
Summit Therapeutics Inc
|
16.98 | 13.17B | 220.00K | -1.08B | -326.53M | -1.4448 |
VRTX
Vertex Pharmaceuticals Inc
|
443.16 | 112.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.29 | 79.21B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
704.31 | 43.71B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
316.09 | 41.92B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
153.32 | 33.05B | 606.42M | -1.28B | -997.58M | -6.403 |
Summit Therapeutics Inc Stock (SMMT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-16 | 다운그레이드 | Jefferies | Buy → Hold |
| 2025-12-17 | 업그레이드 | Barclays | Underweight → Equal Weight |
| 2025-11-18 | 개시 | Wolfe Research | Peer Perform |
| 2025-09-17 | 개시 | Barclays | Underweight |
| 2025-09-04 | 개시 | Guggenheim | Buy |
| 2025-08-19 | 개시 | Piper Sandler | Neutral |
| 2025-07-01 | 개시 | UBS | Buy |
| 2025-06-11 | 개시 | Leerink Partners | Underperform |
| 2025-03-26 | 업그레이드 | Citigroup | Neutral → Buy |
| 2025-03-21 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-03-12 | 개시 | Evercore ISI | Outperform |
| 2025-02-28 | 개시 | Goldman | Buy |
| 2025-01-08 | 개시 | Truist | Buy |
| 2024-12-11 | 개시 | Wells Fargo | Overweight |
| 2024-12-06 | 개시 | Jefferies | Buy |
| 2024-11-04 | 개시 | JMP Securities | Mkt Outperform |
| 2024-09-27 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2024-08-12 | 개시 | H.C. Wainwright | Buy |
| 2024-05-07 | 개시 | Citigroup | Buy |
| 2024-03-26 | 개시 | Stifel | Buy |
| 2018-06-28 | 다운그레이드 | Janney | Buy → Neutral |
| 2018-05-02 | 개시 | Janney | Buy |
| 2018-04-12 | 재확인 | Needham | Buy |
| 2018-02-13 | 개시 | BTIG Research | Buy |
| 2018-01-04 | 개시 | SunTrust | Buy |
| 2017-12-01 | 재개 | H.C. Wainwright | Buy |
| 2016-11-16 | 재확인 | RBC Capital Mkts | Outperform |
| 2016-10-05 | 재확인 | Needham | Buy |
| 2016-09-16 | 개시 | H.C. Wainwright | Buy |
| 2015-03-30 | 개시 | Needham | Buy |
| 2015-03-30 | 개시 | Oppenheimer | Outperform |
모두보기
Summit Therapeutics Inc 주식(SMMT)의 최신 뉴스
Aug Retail: Is Summit Therapeutics Inc undervalued by DCF analysisGap Down & Weekly Sector Rotation Insights - baoquankhu1.vn
Revolution Medicines and Summit Therapeutics Advance Broad RAS(ON) Combo Study in Solid Tumors - TipRanks
Barclays Maintains Summit Therapeutics(SMMT.US) With Hold Rating, Maintains Target Price $18 - Moomoo
Summit Therapeutics Links Ivonescimab Brain Metastases Data To November PDUFA - Sahm
Summit Therapeutics stock drops 3.94% as FDA accepts BLA for Ivonescimab in NSCLC - Traders Union
A Look At Summit Therapeutics (SMMT) Valuation After New Ivonescimab Phase III Data And FDA BLA Filing - Yahoo Finance
What makes Summit Therapeutics (SMMT) one of the best large caps under $30 - MSN
Summit Therapeutics (SMMT) Is Up 6.9% After Phase III Ivonescimab Data And FDA FilingWhat's Changed - Yahoo Finance
Summit Therapeutics (SMMT) climbs 15.4% ahead of pipeline Q2 updates - msn.com
Summit Therapeutics outlines ivonescimab progress with key Phase III data expected mid-2025 - MSN
Summit Therapeutics to present ivonescimab data at ELCC 2026 - StreetInsider
Summit Therapeutics Inc. Announces Multiple Ivonescimab Data Sets from Phase III Studies in Advanced Nsclc Patient Populations to Be Featured At ELCC 2026 - marketscreener.com
Summit lung cancer drug showed 10.1-month brain PFS in Phase III - Stock Titan
SMMT Stock Price, Quote & Chart | SUMMIT THERAPEUTICS INC (NASDAQ:SMMT) - ChartMill
Summit Therapeutics (NASDAQ:SMMT) Raised to Strong-Buy at Truist Financial - MarketBeat
What Makes Summit Therapeutics (SMMT) One of the Best Large Caps Under $30 - Insider Monkey
Aug Sectors: Can Summit Therapeutics Inc be the next market leader - baoquankhu1.vn
5 Large Cap Stocks Under $30 With Huge Upside Potential - Insider Monkey
Summit Therapeutics (SMMT) Climbs 15.4% Ahead of Pipeline Q2 Updates - Insider Monkey
Prediction: 2 Stocks That Will Be Worth More Than Summit Therapeutics 1 Year From Now - Yahoo Finance
Prediction: 2 Stocks That Will Be Worth More Than Summit Therapeutics 1 Year From Now - The Motley Fool
U.S. Markets Rose Wednesday; Summit Therapeutics Topped Leaders - Barron's
Summit Therapeutics Enters Strong Growth Phase Amid Partnerships and Trials - StocksToTrade
Summit Therapeutics (NASDAQ:SMMT) Trading 12.1% HigherHere's What Happened - MarketBeat
Summit Therapeutics Inc. (SMMT) focused on non-small cell lung cancer trial of Ivonescimab - MSN
Axsome Therapeutics faces competition amid FDA review risk for Summit's ivonescimab - Intellectia AI
Summit Therapeutics (SMMT) Stock Price Prediction for 2026, 2030-2040 - Traders Union
347,241 Shares in Summit Therapeutics PLC $SMMT Acquired by Tudor Investment Corp ET AL - MarketBeat
Responsive Playbooks and the SMMT Inflection - Stock Traders Daily
Trade Recap: Does Summit Therapeutics Inc have a sustainable dividend2026 Investor Takeaways & Reliable Volume Spike Trade Alerts - baoquankhu1.vn
Analysts Are Bullish on Top Healthcare Stocks: Scholar Rock Holding (SRRK), Summit Therapeutics (SMMT) - The Globe and Mail
SMMT PE Ratio & Valuation, Is SMMT Overvalued - Intellectia AI
Summit Therapeutics Inc.Common Stock (NQ: SMMT - FinancialContent
Jefferies downgrades Summit Therapeutics (SMMT) - MSN
Should Jefferies’ Downgrade and Ivonesimab Focus Shape Summit Therapeutics’ (SMMT) Risk‑Reward Profile? - simplywall.st
SMMT Downgraded by Jefferies, Price Target Slashed by 64% | SMMT Stock News - GuruFocus
Summit Therapeutics (NASDAQ:SMMT) Rating Lowered to "Hold" at Jefferies Financial Group - MarketBeat
Summit Therapeutics downgraded to Hold from Buy at Jefferies - TipRanks
SMMT SEC FilingsSummit Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Summit Therapeutics (NASDAQ:SMMT) Trading 6.5% HigherTime to Buy? - MarketBeat
How correlated is Summit Therapeutics Inc to the S P5002026 Chart Watch & Advanced Technical Signal Analysis - baoquankhu1.vn
WINTON GROUP Ltd Makes New Investment in Summit Therapeutics PLC $SMMT - MarketBeat
Understanding the Setup: (SMMT) and Scalable Risk - Stock Traders Daily
Summit Therapeutics at The Citizens Life Sciences Conference: Strategic Insights on Ivonescimab - Investing.com Nigeria
Earnings Report: Is Summit Therapeutics Inc impacted by rising ratesQuarterly Portfolio Review & Free Daily Entry Point Trade Alerts - baoquankhu1.vn
Earnings Recap: How correlated is Summit Therapeutics Inc to the S P5002026 Outlook & Reliable Entry Point Alerts - baoquankhu1.vn
Summit Therapeutics’ Earnings Call Highlights OS Hurdles - The Globe and Mail
Summit Therapeutics (NASDAQ:SMMT) Upgraded by Zacks Research to Hold Rating - MarketBeat
Summit Therapeutics (SMMT) ends 2025 with strong cash reserves and increased clinical investment - MSN
Summit Therapeutics PLC (NASDAQ:SMMT) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Aug Outlook: Can Summit Therapeutics Inc stock outperform in a bear marketDollar Strength & Risk Managed Investment Entry Signals - baoquankhu1.vn
Summit Therapeutics Inc (SMMT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.41%
0.04%
자본화:
|
볼륨(24시간):